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Abstract 
 
Chronic skin healing defects are one of the leading challenges to lifelong wellbeing, affecting 2-
5% of populations.  Chronic wound formation is linked to age and diabetes and frequently leads 
to major limb amputation.  Here we identify a strategy to reverse fibroblast senescence and 
improve healing rates.  In healthy skin, fibronectin activates Rac1 in fibroblasts, causing 
migration into the wound bed and driving wound contraction.  We discover that mechanical 
stimulation of skin with ultrasound can overturn healing defects by activating a 
calcium/CamKinaseII/Tiam1/Rac1 pathway that substitutes for fibronectin-dependent signaling 
and promotes fibroblast migration.  Treatment of diabetic and aged mice recruits fibroblasts to 
the wound bed and reduces healing times by 30%, restoring healing rates to those observed in 
young, healthy animals.  Ultrasound treatment is equally effective in rescuing the healing defects 
of animals lacking fibronectin receptors, and can be blocked by pharmacological inhibition of the 
CamKinaseII pathway.  Finally, we discover that the migration defects of fibroblasts from 
human venous leg ulcer patients can be reversed by ultrasound, demonstrating that the approach 
is applicable to human chronic samples.  By demonstrating that this alternative Rac1 pathway 
can substitute for that normally operating in skin, we identify future opportunities for 
management of chronic wounds. 
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Introduction 
 
Chronic healing defects are one of the largest current health challenges, affecting over 6.5 
million patients in the US and costing over US$25 billion annually (Sen et al., 2009).  The major 
risk factors are diabetes, age, obesity and smoking (Galiano and Mustoe, 2007; Sen et al., 2009), 
meaning that the challenge of treating chronic wounds is escalating as the risk factors become 
more common.  Current approaches to wound treatment such as debridement and antibiotic 
treatment to reduce infection and pressure treatment to increase blood flow are effective in some, 
but not all cases.  Topical application of growth factors to activate cells has been disappointing 
due to the abundance of proteolytic enzymes in a chronic wound and while injection of 
mesenchymal stem cells or modified fibroblasts is effective, it is prohibitively expensive 
(Woodley et al., 2007; Zahorec et al., 2014).  Therefore it is important that we discover ways to 
manipulate cell types already in situ.  Acute wound closure can be divided into four main 
processes: inflammation, fibroblast-dependent wound contraction, re-epithelialisation and 
angiogenesis (Shaw and Martin, 2009).  Delays in the healing of acute wounds leads to the 
formation of chronic wounds and examination of the cellular defects of chronic wounds 
highlights a chronic inflammatory response and fibroblast senescence as the two key defects 
(Harding et al., 2005; Menke et al., 2007; Wall et al., 2008).  While current wound therapy 
focuses on management of bacterial burden and the inflammatory response, effective strategies 
for manipulating the fibroblast population are still lacking (Galiano and Mustoe, 2007). 
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Upon wounding, fibronectin deposited by macrophages or leaking from damaged blood vessels 
(Shaw and Martin, 2009) engages D5E1-integrin and syndecan-4 on the surface of fibroblasts, 
activating the Rac1 pro-migratory signal (Bass et al., 2007).  Knockout of syndecan-4 or 
fibroblast-specific knockout of Rac1 retard wound closure (Echtermeyer et al., 2001; Liu et al., 
2009), whereas topical application of fibronectin or overexpression of constitutively active Rac1 
accelerates cutaneous repair (Hassanain et al., 2005; Kwon et al., 2007).  Rac1 plays a central 
role in most cell migration processes and can be activated by a large number of guanine-
nucleotide-exchange factors (GEFs) downstream of a number of signaling pathways 
(Raftopoulou and Hall, 2004).  The range of regulatory mechanisms means that it may be 
possible to activate Rac1 in skin fibroblasts and drive migration by pathways other than the 
fibronectin-dependent route.  One possibility is to use mechanical, rather than chemical stimuli 
to activate Rac1.  Indeed, stimulation of cultured fibroblasts with ultrasound activates Rac1 by a 
syndecan-4-independent mechanism (Mahoney et al., 2009).  Interestingly, clinical trials have 
revealed that ultrasound accelerates fracture repair by 30-40% (Heckman et al., 1994; 
Kristiansen et al., 1997) by promoting endochondral ossification (Azuma et al., 2001; Leung et 
al., 2004), and this approach has received approval for clinical fracture therapy from the FDA 
(US Food and Drug Administration) in 1994 and NICE (UK National Institute for Health and 
Care Excellence) in 2013.  However the possibility that ultrasound might also accelerate soft 
tissue repair has not been investigated. 
 
In this study, we identify a mechanism of Rac1 activation that can substitute for the fibronectin-
dependent pathway that operates in healing of healthy skin.  We demonstrate that activation of 
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the pathway by mechanical stimulation, with ultrasound, rescues healing defects caused by 
diabetes, age or defects in fibronectin signaling by enhancing wound fibroblast migration.  We 
go on to show that such treatments have similar effects on patient chronic wound fibroblasts, 
indicating that such approaches could be efficacious in clinical situations. 
 
Results & Discussion 
 
Acceleration of dermal repair in impaired healing models 
 
To examine the effect of mechanical stimuli on dermal wound closure, we compared the effect of 
a 20-minute daily ultrasound treatment, proven to be efficacious for fracture repair (30 mWcm-2, 
1.5 MHz wave frequency, 1 kHz pulse frequency), with a sham treatment where the device was 
applied, but not activated.  In the absence of a true chronic wound animal model, diabetic mice 
are the most commonly used impaired healing murine model (Ansell et al., 2012).  Non-obese 
diabetic (NOD) mice, which spontaneously develop type-1 diabetes (Atkinson and Leiter, 1999) 
suffered a delay in the closure of 4-mm full-thickness skin punch wounds, compared to non-
diabetic mice (Fig. 1A).  Wound size was significantly reduced at days 6 and 7 in diabetic mice 
that received ultrasound treatment (Fig. 1A+B) and treatment reduced the wound resolution time, 
at which the scab fell off, from 9 to 6 days (Fig. 1C).  Therefore, ultrasound stimulation reduced 
healing times by 33% and restored the healing mechanisms of diabetic animals to those observed 
in healthy controls.  Age is a second key risk factor in poor healing prognosis.  The effect on 18-
month-old mice was even more pronounced, with significant healing retardation of untreated 
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mice at days 3-9, compared with 3-month-old or ultrasound-treated 18-month-old mice (Fig. 1D-
E). Again, ultrasound reduced the wound resolution time from 9 to 6 days (Fig.1F).  These 
results clearly demonstrate that daily ultrasound treatment assists wound closure in terms of both 
wound size, and the time taken for wounds to resolve to levels indistinguishable from young 
mice. 
 
The effect of ultrasound on wound area caused us to examine the effect on early wound 
responses, namely inflammation and wound contraction by fibroblasts.  Ultrasound treatment 
increased the number of fibroblast specific protein (FSP) positive fibroblast cells at the wound 
shoulder at 72 hours post-wounding (Fig. 1G-H, Supplementary Fig. 1A-B), whilst F4/80 
staining of macrophages (Fig. 1I-J, Supplementary Fig. 1C-D) or fibronectin deposition 
(Supplementary Fig. 1E) were unaffected by ultrasound.  Therefore, we conclude that ultrasound 
restores healing to diabetic and aged animals by activating fibroblasts.  The finding fits with our 
clinical understanding of defective healing in diabetes, which has been attributed to fibroblast 
senescence and loss of migratory response, as well as neuropathy and ischemia (Falanga, 2005).  
These findings caused us to look more closely at the effect of ultrasound on fibroblast behavior. 
 
Fibroblast migration is guided by engagement of the fibronectin receptors, D5E1-integrin and 
syndecan-4, which leads to activation of the protrusive signal, Rac1, and is required for efficient 
wound closure (Bass et al., 2007; Echtermeyer et al., 2001; Liu et al., 2009).  We have 
previously demonstrated that ultrasound activates Rac1 in syndecan-4-null fibroblasts and drives 
linear migration in the absence of a fibronectin guidance cue (Mahoney et al., 2009).  Therefore 
© 2015 The Society for Investigative Dermatology
 7 
we examined whether ultrasound can rescue the healing defects of Sdc4 -/- mice.  Sdc4 -/- mice 
suffer a healing delay compared to wild-type, although it is not as severe as that of the diabetic 
and aged mice (Fig. 1K).  Ultrasound treatment accelerated wound closure rate and reduced 
resolution time of Sdc4 -/- mice (Fig. 1K-M) and specifically drove recruitment of fibroblasts 
(Fig. 1N, Supplementary Fig. 2A+B).  By contrast, ultrasound had no effect on wild-type 
animals, which already healed efficiently (Supplementary Fig. 2C-G).  Taken together, we 
demonstrate that the mechanical ultrasound stimulus activates fibroblasts and overcomes wound-
healing defects in both pathological and specific knockout mouse models. 
 
Ultrasound induces persistent migration 
 
In the dermis, collagen and fibronectin are arranged into aligned fibres that act as guidance cues 
and cause linear migration of fibroblasts.  An in vitro approximation of this matrix structure can 
be generated by lysing fibroblasts from a cultured monolayer to yield exposed cell-derived 
matrix (CDM).  CDM allows detailed analysis of ability of individual migrating cells to follow 
fibers, and migration persistence can be calculated by dividing linear displacement of a cell by 
total distance moved.  Wild-type cells migrate persistently over CDM, whereas Sdc4 -/- 
fibroblasts migrate randomly, due to dysregulated Rac1 signaling (Bass et al., 2007).  Ultrasound 
stimulation of wild-type fibroblasts had no effect on speed, and did not significantly increase the 
persistence, as wild-type fibroblasts already exhibit linear migration (Fig. 2A-C, Supplementary 
Movie 1).  Although ultrasound did not affect the speed of Sdc4 -/- fibroblasts, it caused the cells 
to switch from random to persistent migration (Fig. 2D-F), consistent with the recruitment of 
© 2015 The Society for Investigative Dermatology
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fibroblasts to the wound shoulder seen in vivo (Fig. 1M + Supplementary Fig. 2A).  To test 
whether the migration effect is applicable to human chronic wound samples, we repeated the 
experiment using senescent-like fibroblasts isolated from the chronic venous leg ulcer (VLU) of 
a 71-year old female patient with wound duration of greater than 7 months.  With the VLU 
fibroblasts, the effect of ultrasound was even more dramatic than Sdc4 -/- fibroblasts, increasing 
both the speed and persistence of migration (Fig. 2G-I, Supplementary Movie 2).  The increase 
in severity of the migration defect of the chronic sample compared to the Sdc4 -/- sample 
matches the greater effect on healing seen with aged or diabetic mice, compared to Sdc4 -/-.  
Importantly, these results show that although pathological defects are more severe than simple 
knockout models, ultrasound is capable of reactivating fibroblasts and restoring both, so is 
broadly applicable. 
 
Alternative Rac1 Activation Mechanisms 
 
We know that Rac1 activation is a key event in skin repair, and that engagement of syndecan-4 
by fibronectin activates Rac1 in healthy skin fibroblasts.  We also know that ultrasound negates 
the need for syndecan-4 in wound healing, and so we tested whether ultrasound was activating 
Rac1 by an alternative pathway.  Rac1 is activated by exchange of bound GDP for GTP, 
governed by the activity of guanine-nucleotide exchange factors (GEFs) (Raftopoulou and Hall, 
2004), and so we tested the role of a number of GEFs in mediating the ultrasound signal, using 
effector pull-down assays.  Ultrasound elicited a wave of Rac1 activity in control knockdown 
MEFs (Fig. 3A).  Reducing the ultrasound intensity attenuated the 30-minute peak in Rac1 
© 2015 The Society for Investigative Dermatology
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activity, confirming that the Rac1 response was indeed a consequence of the ultrasound wave 
(Supplementary Fig. 3A).  Rac1 activation was not blocked by RNAi of Rac-GEFs, Vav2 or 
Dock180 (Fig. 3B-C, F).  By contrast, Rac1 activation was ablated in Tiam1 -/- MEFs, and could 
be rescued by re-expression of Tiam1 (Fig. 3D-F).  To ensure that ultrasound stimulation was 
coupled to signaling downstream of Rac1, phosphorylation of p21 activated kinase 1 (PAK) was 
measured be in-cell ELISA.  Ultrasound induced PAK phosphorylation that was blocked by 
knockout of Tiam1, but not knockdown of other GEFs (Fig. 3G-K).  Finally, specificity of the 
ultrasound signal was tested by examining the related GTPase, Cdc42.  Ultrasound had no effect 
on Cdc42 activity (Supplementary Fig. 3B), demonstrating a specific effect on Rac1. 
 
CaMKII mediates the ultrasound response 
 
Tiam1 is activated by phosphorylation by protein kinase C (PKC) and calmodulin kinase II 
(CaMKII) (Fleming et al., 1999).  We have previously reported that ultrasound functions 
independently of PKC (Mahoney et al., 2009), and so we investigated the role of CaMKII.  
Inhibition of CaMKII activity with the pharmacological inhibitor, KN93, or siRNA blocked PAK 
phosphorylation upon ultrasound stimulation (Fig. 4A-C).  Furthermore, ultrasound triggered 
activating autophosphorylation of CamKII (Thr286) demonstrating that CamKII mediates the 
ultrasound effect (Fig. 4D). 
 
CaMKII is itself activated by association with calcium-bound calmodulin (Swulius and Waxham, 
2008), leading us to test whether calcium levels affected the ultrasound response.  Disruption of 
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the intracellular calcium stores (thapsigargin), chelation of extracellular calcium (BAPTA) or 
chelation of all calcium (membrane permeable, BAPTA-AM) each blocked PAK 
phosphorylation in response to ultrasound, demonstrating that calcium flux plays a key role in 
mediating the ultrasound signal (Fig. 4E).  Crucially, thapsigargin and BAPTA had no effect on 
PAK-phosphorylation in response to fibronectin fragments (Fig. 4F), demonstrating that the cells 
were still capable of mounting a response and that ultrasound and fibronectin activate Rac1 by 
separate pathways.  Collectively, these experiments identify a calcium-dependent pathway of 
Rac1 activation that is independent of the fibronectin-triggered pathway that occurs in healthy 
fibroblasts (Fig. 4G).   
 
Healing signals converge on Rac1 
 
We propose that ultrasound-triggered signals and normal wound signals converge on the key 
migration regulator, Rac1, explaining how ultrasound can rescue wound healing defects arising 
from a number of situations.  We tested the hypothesis by blocking the ultrasound-triggered 
pathway in our mouse models.  Application of the pharmacological Rac1 inhibitor, EHT 1864, to 
wounds on wild-type mice severely retarded wound contraction and furthermore blocked the 
ability of ultrasound to rescue healing, demonstrating that normal and ultrasound-induced 
pathways converge on Rac1 (Fig. 5A).  Fibronectin-dependent and ultrasound-dependent 
pathways were tested using a combination of syndecan-4 knockdown and pharmacological 
inhibition of CamKII with KN93.  KN93 had no effect on wound closure in wild-type mice 
where fibronectin signaling was intact (Fig. 5B).  However, in Sdc4 -/- mice where fibronectin 
© 2015 The Society for Investigative Dermatology
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signaling is perturbed, KN93 blocked the ability of ultrasound to rescue normal wound closure 
(Fig. 5C).  These results demonstrate that Rac1 activation is crucial for efficient wound closure, 
but that it can be achieved in different ways.  In the absence of signaling through syndecan-4, 
stimulation of a CamKII pathway is a viable route for Rac1 activation and ultrasound treatment 
provides a robust mechanism for doing that. 
 
Collectively our experiments demonstrate that Rac1 can be activated in wound fibroblasts using 
a mechanical, ultrasound stimulus.  This calcium-CamKII-Tiam1-mediated pathway can 
substitute for the fibronectin triggered pathway seen during the healing of healthy skin and 
restores normal healing to a number of pathological healing mouse models. 
 
Comparison to the fracture-repair registry 
 
The standout discovery in this manuscript is that healing times in diabetic or aged mice can be 
reduced by 33% (Fig. 1), which is comparable with the 30-40% reduction in healing times of 
tibial and radial fractures (Heckman et al., 1994; Kristiansen et al., 1997).  The similarity is 
surprising as the mechanisms differ.  We demonstrate that in skin healing, ultrasound stimulates 
Rac1 signalling and fibroblast migration, but has no effect on macrophage recruitment.  By 
contrast, ultrasound in fracture repair has been linked to inflammatory signals and induces COX-
2 expression and prostaglandin E2 secretion (Tang et al., 2006), resulting in differentiation of 
mesenchymal cells into osteoblasts and chondrocytes that leads to endochrondal ossification 
(Pounder and Harrison, 2008).  Nevertheless, the rescue of skin healing that we report matches 
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the reported restoration of delayed fracture healing caused by diabetes (Coords et al., 2011) or 
age (Naruse et al., 2010) in rodents.  A second feature of our findings is that ultrasound has 
limited effect on the healing rates of young healthy mice, which already heal efficiently (Fig. 
S2C+D).  Registry studies of clinical investigations into the use of ultrasound for fracture repair 
have revealed similar trends.  While the clinical study by Heckman et al. demonstrated that 
ultrasound accelerated fracture healing in patients by 38% (Heckman et al., 1994), another study 
that excluded risk factors such as smoking and alcohol from the study group did not find a 
significant effect of ultrasound on fracture repair (Emami et al., 1999).  The similarities between 
groups that benefit from ultrasound treatment during fracture and skin repair are encouraging as 
inspection of a large FDA-reviewed registry of non-union fractures treated with ultrasound 
reveals that although untreated fractures heal 63-87% less efficiently in diabetic than healthy 
patients, ultrasound induced closure of non-unions in 82% (71/87) of diabetics, similar to the 
83% (1283/1546) closure rate observed across the entire registry (Frankel and Mizuho, 2002).  
If, as our findings suggest, the beneficial effect of ultrasound can be extrapolated from fracture to 
skin healing, then a solution to treatment of chronic wounds would be within our grasp. 
 
An issue that has hindered the clinical use of ultrasound is that different studies have used a 
range of ultrasound parameters with a range of success.  Efficacy in fracture repair has been 
demonstrated using ultrasound intensities ranging from 2 mW/cm2 to 500 mW/cm2 (Angle et al., 
2011; Claes and Willie, 2007) although intensities above 100 mW/cm2 have been reported to 
result in lower maximum torque in the repaired bone than intensities of 30-50 mW/cm2 (Claes 
and Willie, 2007).  Previous studies into effects on skin healing have been even more diverse, 
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with most studies examining low-frequency ultrasound as a form of physiotherapy massage.  
One study using high frequency (3 MHz) ultrasound actually found that treatment retarded 
healing of ischemic skin flap wounds in rats (Altomare et al., 2009) but this study applied 
ultrasound at 500 mW/cm2.  At below 50 mW/cm2 the thermal effects of ultrasound are 
negligible (0.01°C (Duarte, 1983)), but at 500 mW/cm2 would be sufficient to affect 
temperature-sensitive enzymes such as matrix metalloproteinases and collagenase (Claes and 
Willie, 2007).  It is logical that an ischemic wound would be more susceptible to such damage, 
due to the reduced ability to dissipate heat. 
 
In this study, we find that reduction of ultrasound intensity attenuates Rac1 activation in 
fibroblasts (Supplementary figure 3A).  By contrast, signals as low as 2 mW/cm2 have been 
reported to be sufficient to trigger differentiation and mineralisation of bone marrow stromal 
cells (Angle et al., 2011).  One possible explanation would be that molecular mechanisms differ 
between bone and skin healing, but a second would be that a threshold of active Rac1 is required 
to activate a cell, and that 2 mW/cm2 is sufficient to reach that threshold in stromal cells.  Indeed, 
we previously reported that the threshold for focal adhesion-formation by fibroblasts is 20-25 
mW/cm2 (Mahoney et al., 2009).  The threshold differences between cell types mean that the 
ultrasound dose needs to be optimised, and is even more complicated in vivo.  Ultrasound is 
attenuated as it passes through tissue, and then reflected at the bone-soft tissue interface (Claes 
and Willie, 2007).  Such effects mean that the same emitter delivers different intensities of 
ultrasound at a skin compared to a fracture, and it is probable that the optimal regimes for 
treating fractures and skin wounds will differ.  Therefore, our current findings represent the first 
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step towards skin healing therapy and there is now great scope and great need for refinement, to 
develop the optimal therapeutic regimes for both skin and bone treatments. 
 
 
Materials & Methods 
 
Animals 
 
Animal experiments were performed in accordance with Home Office regulations described by 
the UK Animals (Scientific Procedures) Act 1986, UK project license 30/2791.  Syndecan-4 
wild-type and knockout C57BL/6J mice (Ishiguro et al., 2000) generated by heterozygous (Sdc4 
(+/-) C57BL/6J) parental crosses were used at age 12 weeks for comparison of genotypes.  Wild-
type mice were used at 18 months for the ageing study.  Male NOD mice were maintained in a 
clean environment to maximize spontaneous diabetes development. Onset of diabetes was 
monitored weekly prior to experiments by urine glucose measurements (Diastix, Bayer), and 
daily thereafter until sacrifice. 
 
Punch wound experiments 
 
Mice were anaesthetized by isofluorane inhalation for initial wounding and daily treatment with 
ultrasound.  To create wounds, two pairs of full-thickness 4mm excisional punch wounds were 
made either side of the dorsal midline of the barbered back of each animal. Wound size was 
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recorded by photographing mice at the same time each day prior to treatment.  Where relevant, 
rate constants of curves were calculated by fitting a one-phase decay with GraphPad Prism.  For 
application of drugs, 30% pluronic gel (Sigma) with and without 50PM EHT1864 (Sigma) or 
20PM KN93 (Calbiochem) was maintained as a liquid at 4qC before it was administered directly 
to the wound by pipette immediately after wounding and allowed to solidify. 
 
Ultrasound stimulation 
 
Mouse wounds or cells in culture were coupled to 2.5-cm diameter ultrasound transducer 
(Exogen; Bioventus LLC, Durham, NC) using water-based gel (Exogen).  During stimulation 
experiments, the transducer generated 30 mW/cm2 (spatial average, temporal average) pulsed 
ultrasound with a 1.5 MHz wave frequency, pulsed at 1 kHz for a duration of 20 minutes.  For 
sham treatments, the transducer was applied, but not activated.  For intensity investigations, a 
similar device with variable power output (30, 15, 6 and 2 mW/cm2) was used. 
 
Immunohistochemistry 
 
10-Pm sections of 4% paraformaldehyde-fixed, paraffin-embedded skin were immunostained 
with antibodies against FSP1 and macrophage marker, F4/80 (Abcam) and fibronectin 
(Millipore).  Primary antibody binding was visualized with biotinylated secondary antibody, 
ABC-HRP conjugate and 3,3-diaminobenzidine developing reagent (Vector Laboratories), and 
sections counterstained with haematoxylin (Sigma). 
© 2015 The Society for Investigative Dermatology
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Cell culture 
 
Tiam1 wild-type and knockout MEFs were cultured at 37qC in DMEM, 10% fetal bovine serum, 
4.5 g/l glucose, 2 mM L-glutamine.  Immortalized wild-type and syndecan-4-knockout MEFs, 
generated as previously described (Bass 2007), were cultured at 33qC to preserve temperature 
dependent expression of large T antigen driven immortality in DMEM, 10% fetal bovine serum, 
4.5 g/l glucose, 2 mM L-JOXWDPLQHDQG8PO,)1Ȗ6LJPDChronic wound fibroblasts were 
obtained from tissue biopsies after approval from the Local Research Ethics Committee 
(09/WSE03/19) and written informed consent from patients with non-healing, chronic venous leg 
ulcers attending the Wound Healing Clinic at the University Hospital of Wales, Cardiff.  Only 
patients with wounds that failed to respond to conventional treatment regimes after 2 months 
were used in the study.  Chronic wound fibroblasts were isolated and cultured as described 
previously (Cook et al., 2000).  Telomerase-immortalized human fibroblasts were cultured at 
37qC in DME, 15% fetal bovine serum, 4.5 g/l glucose, 25 mM HEPES and 2 mM L-glutamine. 
 
siRNA duplexes with ON TARGETTM modification, targeting the sense strand of mouse Vav2 
(CAAAUGGGCGGAUCGGUUGUU) and Dock180 (GAUAUUGAUCGGUUACAUAUU), 
were purchased from Dharmacon (Thermo Fisher Scientific).  For knockdown of CamKII, both 
A and B subunits were targeted by esiRNA (Sigma).  siRNAs were transfected into immortalized 
MEFs over two rounds using Dharmafect2 reagent (Thermo Fisher Scientific).  Expression of 
target proteins in comparison with mock-transfected cells was tested by Western blotting. 
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Migration analysis 
 
CDM was prepared as described previously by culturing confluent fibroblasts for 10 days before 
removing the fibroblasts by NH4OH lysis (Bass et al., 2007).  For migration, cells were seeded 
at 5000 cells/ml and allowed to spread for 4 hours before capturing time-lapse images at 10-
minute intervals for 16 hours on a Leica AS MDW microscope using a 5x NA 0.15 Fluotar 
objective and Roper CCD camera.  The migration paths of all non-dividing, non-clustered cells 
were tracked using ImageJ software.  Persistence was calculated by dividing linear displacement 
of a cell over 10 hours by the total distance migrated. 
 
Cell spreading for biochemical assays 
 
GTPase and PAK-activation assays were conducted on surfaces coated with a recombinant 
fibronectin polypeptide encompassing type III repeats 6-10 that comprises the D5E1-integrin 
ligand (Bass et al., 2007).  6-well or 96-well tissue culture-treated plastic dishes (Corning BV) 
were coated overnight at 4°C with 20 Pg/ml 50K in Dulbecco's PBS containing calcium and 
magnesium (Sigma), and blocked with 10 mg/ml heat-denatured BSA.  To prevent de novo 
synthesis of ECM and other syndecan-4 ligands, cells were treated with 25 Pg/ml cycloheximide 
(Sigma) for 2 hours prior to the assay. Cells were spread on the 50K-coated plates for 2 hours in 
DMEM, 4.5 g/l glucose, 25 mM HEPES, 25 Pg/ml cycloheximide.  Spread cells were stimulated 
with ultrasound (30 mWcm-2, 1.5 MHz wave frequency, 1 kHz pulse frequency), or the 
© 2015 The Society for Investigative Dermatology
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syndecan-4-binding fragment of fibronectin (Bass et al., 2007).  Where appropriate, 
pharmacological inhibitors were included throughout spreading and stimulation:  20PM  KN93 
(Calbiochem), 200 nM Thapsigargin (Calbiochem), 50PM BAPTA, 50PM BAPTA-AM (Life 
Technologies). 
 
GTPase activity assays 
 
Cells were lysed in 20 mM HEPES (pH 7.4), 10% (v/v) glycerol, 140 mM NaCl, 1% (v/v) 
Nonidet P-40, 0.5% (w/v) sodium deoxycholate, 4 mM EGTA, 4 mM EDTA, cOmplete protease 
inhibitor.  GST-PAK-CRIB-loaded agarose beads were incubated with the lysates for 1 hour and 
then washed 3 times with lysis buffer.  Bound proteins were blotted for Rac1 or Cdc42 (BD 
Transduction Labs). 
 
In-cell ELISA 
 
Cells fixed in 4% PFA were permeablized with 0.1% Triton X-100 in TBS and blocked to reduce 
non-specific binding (Sigma casein block in TBS).  Anti-phospho-Serine141 PAK1/2/3 antibody 
(Life Technologies, diluted 1:800 in TBS-block was applied to each well overnight.  Cells were 
washed in TBS containing 0.1% Tween-20 and primary antibody binding was visualized with 
Alexa-fluor 800-conjugated anti-rabbit IgG diluted 1:5000 in TBS-block.  Wells were washed of 
unbound secondary antibody and the plates scanned quantified (Odyssey fluorescent detection 
system, LI-COR Biosciences). 
© 2015 The Society for Investigative Dermatology
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Figure Legends 
 
Fig. 1:  Rescue of defective healing in mouse models.  4-mm full-thickness punch wounds on 
mice with characterized healing defects or matched controls were subjected to daily ultrasound 
or sham treatments and wound closure was recorded.  (A-C,G+I) Diabetic (NOD). (D-F,H+J) 18-
month and 3-month old. (K-N) Sdc4 -/- and +/+.  (A-B,D-E,K-L) Daily macroscopic images and 
measurements of wound area.  (C,F,M) Animals scored for loss of the scab as an indicator of 
wound resolution.  (G-J,N)  Skin sections stained for fibroblast-specific protein (FSP) and 
macrophages (F4/80) at 72 hours post-wounding, and scored for fibroblast or macrophage 
number per field of view.  Example images shown in figure S1+S2A-B+E-F).  Data are 
representative of 12 wounds in 6 mice per condition.  Error bars indicate s.e.m.  Significance 
tested by Students T-test, *=p<0.05, **=p<0.005. 
 
Fig. 2.  Restoration of defective fibroblast migration.  Sham or ultrasound-treated wild-type 
(A-C), Sdc4 -/- (D-F), or chronic venous leg ulcer fibroblasts (G-I) were seeded onto fibrous cell 
derived matrix and migration tracked over 16 hours. (A, D, G) Example tracks. (B, E, H) 
Average migration speed (total distance moved/time).  (C, F, I) Average persistence of migration 
(total displacement/total distance moved, so that for perfect linear migration, persistence =1).  
Error bars indicate s.e.m., n=60 per condition. Significance tested by Kruskal-Wallis test, 
**=p<0.005, ***=p<0.0005. 
 
© 2015 The Society for Investigative Dermatology
 24 
Fig. 3. Tiam1 mediates Rac1 activation in response to ultrasound.  MEFs were spread on the 
integrin-binding fragment of fibronectin, stimulated with ultrasound and analyzed at the 
appropriate time from the start of stimulation.  (A-E) Rac1 activity measured by effector pull-
down assay, n=5 per condition (F) Expression of candidate GEFs in the corresponding 
experiments. (G-K)  PAK phosphorylation measured by in-cell ELISA, n=12 per condition.  
Error bars indicate s.e.m. Significance tested by ANOVA, *=p<0.05, **=p<0.005. 
 
Fig. 4. CamKII mediates Rac1 activation in response to ultrasound.  Inhibitor-treated MEFs 
were stimulated with ultrasound and analyzed by in-cell ELISA.  (A-C) PAK activation 
IROORZLQJWUHDWPHQWZLWKYHKLFOHRUȝ0.1&DP.,,LQKLELWRUQ $RUNQRFNGRZQ
of CamKII, n=24 (B).  Confirmation of CamKII knockdown (C).  (D) Ultrasound induces 
autophoshorylation of CamKII and can be blocked by KN93, n=16. (E-F) Treatment with 200 
nM thapsigargin, 50PM  BAPTA, or 50PM  BAPTA-AM blocks PAK phosphorylation in 
response to ultrasound, n=5 (E), but thapsigargin and BAPTA do not block PAK 
phosphorylation in response to the syndecan-4-binding fragment of fibronectin, n=4 (F).  (G) 
Mechanical (ultrasound) and chemical (fibronectin) stimuli activate Rac1 by different pathways.  
Error bars indicate s.e.m. Significance tested by ANOVA, *=p<0.05, ***=p<0.0005. 
 
Fig. 5. Independent Rac1 activation pathways drive wound closure in mice.  4-mm full-
thickness punch wounds on wild-type (A+B) or Sdc4 -/- (C+D) mice were treated with vehicle of 
pharmacological inhibitor, 50PM EHT 1864 (A) or 20PM  KN93 (B-D) in pluronic gel.  Wounds 
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were subjected to daily ultrasound or sham treatments and wound closure was recorded. (D) Rate 
constants of curves depicted in (C).  Data are representative of 6 mice per condition.  Error bars 
indicate s.e.m.  (A) Significance of + vs - EHT tested by paired T-test, (C) Significance of 
+KN93+US vs +US tested by paired T-test, *=p<0.05, **=p<0.005. 
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